{"id":"W4407081872","doi":"10.1158/2767-9764.crc-24-0601","title":"Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; F. Hoffmann-La Roche","keywords":"Pembrolizumab; Metastatic melanoma; Medicine; Oncology; Melanoma; Internal medicine; Immunotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003238551,0.0001276858,0.0005571299,0.000455984,0.0002547245,0.00001301036,0.0002748526,0.00002590145,0.00008462821],"category_scores_gemma":[0.0001734134,0.0000889849,0.00008252879,0.0009653236,0.0004121938,0.00006204122,0.000122863,0.0001163243,7.020377e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002155196,"about_ca_system_score_gemma":0.000565015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007255431,"about_ca_topic_score_gemma":0.002105638,"domain_scores_codex":[0.9986369,0.0002355986,0.0004125882,0.0002066553,0.0002975003,0.0002107533],"domain_scores_gemma":[0.9966603,0.0007817244,0.0001260128,0.001453562,0.0008857785,0.00009261962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1217308,0.1618581,0.009127805,0.003553195,0.01688629,0.0000647261,0.0214922,0.0003529481,0.285232,0.01374196,0.002669642,0.3632904],"study_design_scores_gemma":[0.4689638,0.1964366,0.01527348,0.007385116,0.00624636,0.00003624519,0.07684147,0.01799803,0.1678768,0.001581659,0.04041294,0.0009474728],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898235,0.002734144,0.0001860961,0.00371649,0.000005453114,0.002488291,0.0002108169,0.00002075893,0.0008145032],"genre_scores_gemma":[0.9924467,0.002149913,0.001304917,0.00003531423,0.000005747154,0.001985325,0.0001420113,0.00001486849,0.001915182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3623429,"threshold_uncertainty_score":0.3628699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1569885752029877,"score_gpt":0.5087172314434762,"score_spread":0.3517286562404885,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}